ClinicalTrials.gg
Drug

Infigratinib clinical trials

Also written BGJ398.

studies test it
30
open now
3
in phase 3
4
first study started
2009

How each study uses infigratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the infigratinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 May 2021 · TRUSELTIQ · NDA 214622 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Infigratinib
14
Infigratinib 0.25 mg/kg/day
2
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea
2

Brand

Truseltiq
1

Development codes

BGJ398
20
BBP-831
1

Other names

N'-(2,6-Dichloro-3,5-dimethoxyphenyl)-N-(6-(4-(4-ethylpiperazin-1-yl)anilino)pyrimidin-4-yl)-N-methylurea Phosphate (1:1)
1

Studies by the year they started

29 studies that test it; most in 2020 (7)

Studies that test infigratinib, by start year
YearStudies
20091
20121
20132
20144
20151
20161
20181
20192
20207
20213
20233
20241
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
11
Phase 2
18
Phase 3
4
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 13

QED Therapeutics, a BridgeBio company (5) · Novartis Pharmaceuticals (5) · QED Therapeutics, Inc. (3) · Memorial Sloan Kettering Cancer Center (2) · M.D. Anderson Cancer Center (2) · LianBio LLC (2) · Sameek Roychowdhury (1) · Pfizer (1)

Often tested with

Tested in the same studies.

Encorafenib (1) · Binimetinib (1) · Ribociclib (1) · Buparlisib (1) · Capmatinib (1) · Alpelisib (1) · Tamoxifen (1) · Bevacizumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test infigratinib, phase 3 first.

Studies

Open first, then newest update. How each study uses infigratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 30

See all 30 studies that test infigratinib →

Codes

What other systems call infigratinib · ClinicalTrials.gg INT005959

  • MeSH (NLM) C568950infigratinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) A4055ME1VKINFIGRATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2550729One source FDA
  • Wikidata Q27075200infigratinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C88302InfigratinibOne source FDA
  • DrugBank DB11886One source Wikidata

Also registered as infigratinib phosphate (UNII 58BH47BV6S).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.